- Volume 15 Issue 19
DOI QR Code
Prognostic Value of C-Reactive Protein in Esophageal Cancer: a Meta-analysis
- Zheng, Tian-Liang (Department of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University) ;
- Cao, Ke (Department of Laboratory Medicine, Zhengzhou Hospital of Traditional Chinese Medicine) ;
- Liang, Cui (Department of Cardiology, the First Affiliated Hospital of Zhengzhou University) ;
- Zhang, Kai (Department of Respiratory Medicine, the First Affiliated Hospital of Zhengzhou University) ;
- Guo, Hai-Zhou (Department of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University) ;
- Li, De-Ping (Department of Acupuncture, Zhengzhou Hospital of Traditional Chinese Medicine) ;
- Zhao, Song (Department of Thoracic Surgery, the First Affiliated Hospital of Zhengzhou University)
- Published : 2014.10.23
Background: The classical inflammatory biomarker, C-reactive protein (CRP), has been identified to be related to progression of esophageal cancer. Some research showed that elevated pretreatment serum CRP indicated a poor prognosis, but results have been inconsistent. Materials and Methods: We searched the Medline, Embase and the Cochrane Central Search Library for suitable studies and a meta-analysis of eleven (1,886 patients) was conducted to examine the relationship between elevated serum CRP level and overall survival (OS) in esophageal cancer cases. Moreover, correlation analyses were conducted to assess links between pretreatment serum CRP level and tumor node metastasis (TNM) stage as well as T, N, M grade, respectively. Results: The pooled analysis showed that elevated pretreatment serum CRP level was significantly associated with poorer overall survival (HR 2.09, 95%CI 1.52-2.87, p<0.01). Subgroup analyses were conducted by "country", "cut-off value", "treatment" and "number of patients", and no single factor could alter the result. Elevated pretreatment serum CRP was significantly correlated with more advanced TNM stage and T, N, M grade respectively. Conclusions: Elevated pretreatment serum CRP levels are associated with poorer prognosis in esophageal cancer patients, and could serve as a useful biomarker for outcome prediction.
C-reactive protein;esophageal cancer;prognosis;meta-analysis
- Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
- Chen XL, Liao YQ, Liu JR (2014). Genotype CC of rs1800947 in the C-reactive protein gene may increase susceptibility to colorectal cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 2663-7. https://doi.org/10.7314/APJCP.2014.15.6.2663
- Dai J, Tang K, Xiao W, et al (2014). Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 3369-75. https://doi.org/10.7314/APJCP.2014.15.8.3369
- Feng JF, Zhao HG, Liu JS, et al (2013). Significance of preoperative C-reactive protein as a parameter in patients with small cell carcinoma of the esophagus. Onco Targets Ther, 6, 1147-51.
- Fujiwara H, Suchi K, Okamura S, et al (2011). Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol, 103, 62-8. https://doi.org/10.1002/jso.21751
- Gabay C, Kushner I (1999). Acute-phase proteins and other systemic responses to inflammation. N Engl J Med, 340, 448-54. https://doi.org/10.1056/NEJM199902113400607
- Gockel I, Dirksen K, Messow CM, et al (2006). Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol, 12, 3746-50.
- Guillem P, Triboulet JP (2005). Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus, 18, 146-50. https://doi.org/10.1111/j.1442-2050.2005.00474.x
- Hu Q, Gou Y, Sun C, et al (2014). The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis. Urol Oncol, 32, 1-8. https://doi.org/10.1016/j.urolonc.2013.08.027
- Guo YZ, Pan L, Du CJ, et al (2013). Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev, 14, 243-8. https://doi.org/10.7314/APJCP.2013.14.1.243
- Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
- Holmes RS, Vaughan TL (2007). Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol, 17, 2-9.
- Iimura Y, Saito K, Fujii Y, et al (2009). Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol, 181, 1004-12. https://doi.org/10.1016/j.juro.2008.10.156
- Ikeda M, Natsugoe S, Ueno S, et al (2003). Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg, 238, 197-202.
- Janeway CA, Jr., Medzhitov R (2002). Innate immune recognition. Annu Rev Immunol, 20, 197-216. https://doi.org/10.1146/annurev.immunol.20.083001.084359
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Lyronis ID, Baritaki S, Bizakis I, et al (2005). Evaluation of the prevalence of human papillomavirus and Epstein-Barr virus in esophageal squamous cell carcinomas. Int J Biol Markers, 20, 5-10.
- Mayne ST, Navarro SA (2002). Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr, 132, 3467-70.
- Nakatsu T, Motoyama S, Maruyama K, et al (2012). Tumoral CRP expression in thoracic esophageal squamous cell cancers is associated with poor outcomes. Surg Today, 42, 652-8. https://doi.org/10.1007/s00595-012-0147-3
- Meng YQ, Cao X, Wen ZS, et al (2014). Preoperative level of serum amyloid A is superior to C-reactive protein in the prognosis of esophageal squamous cell carcinoma. Dis Esophagus, 27, 670-7. https://doi.org/10.1111/dote.12128
- Miyata H, Yamasaki M, Kurokawa Y, et al (2011). Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med, 2, 879-85.
- Motoyama S, Mori K, Kamei T, et al (2013). Evaluation of the risk of lymph node metastasis using CRP 1846C>T genetic polymorphism in submucosal thoracic esophageal squamous cell carcinoma. Ann Surg Oncol, 20, 1978-84. https://doi.org/10.1245/s10434-012-2765-9
- Nozoe T, Korenaga D, Futatsugi M, et al (2003). Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker. Cancer Lett, 192, 89-95. https://doi.org/10.1016/S0304-3835(02)00630-4
- Nozoe T, Saeki H, Sugimachi K (2001). Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg, 182, 197-201. https://doi.org/10.1016/S0002-9610(01)00684-5
- Shimada H, Nabeya Y, Okazumi S, et al (2003). Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol, 83, 248-52. https://doi.org/10.1002/jso.10275
- Song ZB, Lin BC, Li B, et al (2013). Preoperative elevation of serum C-reactive protein as an indicator of poor prognosis for early-stage esophageal squamous cell carcinoma. Kaohsiung J Med Sci, 29, 662-6. https://doi.org/10.1016/j.kjms.2013.01.016
- Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603-5. https://doi.org/10.1007/s10654-010-9491-z
- Yu Q, Yu XF, Zhang SD, et al (2013). Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 5735-40. https://doi.org/10.7314/APJCP.2013.14.10.5735
- Vakkila J, Lotze MT (2004). Inflammation and necrosis promote tumour growth. Nat Rev Immunol, 4, 641-8. https://doi.org/10.1038/nri1415
- Vallbohmer D, Lenz HJ (2006). Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus, 19, 425-32. https://doi.org/10.1111/j.1442-2050.2006.00622.x
- Wang CY, Hsieh MJ, Chiu YC, et al (2009). Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol, 92, 270-5. https://doi.org/10.1016/j.radonc.2009.01.002
- Zeh HJ, 3rd, Lotze MT (2005). Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother, 28, 1-9. https://doi.org/10.1097/00002371-200501000-00001
- Zheng Z, Zhou L, Gao S, et al (2013). Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci, 10, 653-64. https://doi.org/10.7150/ijms.6050
- Zhou B, Liu J, Wang ZM, et al (2012). C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One, 7, 43075. https://doi.org/10.1371/journal.pone.0043075
- Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis vol.23, pp.2, 2016, https://doi.org/10.1245/s10434-015-4869-5
- Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging vol.34, pp.6, 2017, https://doi.org/10.1007/s12032-017-0976-4
- Preoperative Plasma Fibrinogen is Associated with Lymph Node Metastasis and Predicts Prognosis in Resectable Esophageal Cancer vol.41, pp.8, 2017, https://doi.org/10.1007/s00268-017-3991-x
- The prognostic role of pretreatment thrombocytosis in gastric cancer vol.97, pp.31, 2018, https://doi.org/10.1097/MD.0000000000011763